For the quarter ending 2026-03-31, JAZZ had $452,400K increase in cash & cash equivalents over the period. $388,500K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 293,100 | 203,451 | 251,412 | -811,011 |
| Acquired in-process research and development | - | 0 | 42,500 | 905,362 |
| Intangible asset amortization | 172,300 | 169,742 | 168,368 | 316,551 |
| Share-based compensation | 74,500 | 70,854 | 88,125 | 132,154 |
| Acquisition accounting inventory fair value step-up adjustment | 37,500 | 40,604 | 40,355 | 66,989 |
| Provision for losses on accounts receivable and inventory | 14,200 | 4,114 | 8,223 | 6,771 |
| Depreciation | 9,100 | 9,427 | 9,878 | 22,331 |
| Non-cash interest expense | 4,700 | 5,329 | 5,299 | 21,914 |
| Deferred tax benefit | -66,200 | -63,309 | -271,410 | -110,252 |
| Operating lease liabilities, less current portion | - | - | -3,475 | -2,887 |
| Impairment of property, plant and equipment | - | 0 | - | - |
| Gain on sale of priority review voucher | 122,800 | - | - | - |
| Other non-current liabilities | - | - | 529 | 4,763 |
| Operating lease assets | - | - | -3,178 | -12,440 |
| Other non-cash transactions | -3,900 | 4,955 | -1,016 | -7,042 |
| Other non-current assets | - | - | -18,824 | 802 |
| Accounts receivable | 6,500 | 65,813 | 50,996 | -10,530 |
| Inventories | 77,800 | -7,720 | 31,909 | 61,852 |
| Prepaid expenses and other assets | -51,900 | -27,492 | 6,674 | -8,212 |
| Accounts payable | -21,400 | -28,972 | 62,358 | 6,465 |
| Accrued liabilities | -7,900 | 26,170 | 126,277 | -75,351 |
| Income taxes payable | 37,400 | -34,784 | 12,738 | 59,270 |
| Other liabilities | 12,200 | 28,018 | - | - |
| Asset acquisition, net of cash acquired | - | 0 | 0 | 858,053 |
| Net cash provided by operating activities | 408,200 | 362,518 | 474,616 | 518,639 |
| Acquired in-process research and development | - | 0 | 42,500 | 0 |
| Proceeds from maturity of investments | 520,000 | 180,000 | 400,000 | 780,000 |
| Proceeds from sale of priority review voucher | 200,000 | 28,167 | - | - |
| Payments related to sale of priority review voucher | 77,200 | - | - | - |
| Purchases of property, plant and equipment | 19,700 | 16,729 | 15,175 | 26,848 |
| Acquisition of investments | 500,000 | 510,100 | 640,125 | 680,050 |
| Acquisition of intangible assets | 0 | 53,500 | 30,000 | 25,000 |
| Share repurchases | - | 0 | 0 | 125,023 |
| Net cash provided by (used in) investing activities | 123,100 | -372,162 | -327,800 | -809,951 |
| Payment of employee withholding taxes related to share-based awards | 103,600 | 1,996 | 3,812 | 69,412 |
| Repayments of long-term debt | 7,800 | 7,750 | 7,750 | 765,500 |
| Proceeds from employee equity incentive and purchase plans | 32,900 | 85,186 | 733 | 21,944 |
| Repayment of 2024 notes | - | 0 | 0 | - |
| Payment of debt modification costs | - | 0 | - | - |
| Net proceeds from issuance of 2030 notes | - | 0 | 0 | - |
| Net cash used in financing activities | -78,500 | 75,440 | -10,829 | -937,991 |
| Effect of exchange rates on cash and cash equivalents | -400 | 33 | 203 | 6,319 |
| Net increase (decrease) in cash and cash equivalents | 452,400 | 65,829 | 136,190 | -1,222,984 |
| Cash and cash equivalents, at beginning of period | 1,391,900 | 1,326,070 | 2,412,864 | - |
| Cash and cash equivalents, at end of period | 1,844,300 | 1,391,899 | 1,326,070 | - |
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)